• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Long COVID plays role in severe and selective neuropsychological impairments

Article

Self-reported survey data “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported.

Image Credit: © Khunatorn - stock.adobe.com

Survey data that was self-reported by 54 individuals who responded to the survey “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported. (Image credit: Adobe Stock/Khunatorn)

Marie-LuiseKieseler and Brad Duchaine, PhD students from Dartmouth College, Hanover, NH, reported that COVID-19 can cause severe and selective neuropsychological impairments after long COVID.1 These impairments can be life-altering and persistent.

They described the case of a 28-year-old woman, Annie, who had normal face recognition, ie, prosopagnosia, before she developed COVID-19 in March 2020. Two months later, she noticed that she was having difficulties recognizing faces when her COVID-19 symptoms relapsed. The problems with face recognition have persisted.

Kieseler and Duchaine assessed Annie’s abilities to recognize faces using 4 tests: a famous faces test and a Doppelganger test to assess her long-term face identity recognition abilities, and 2 tests of unfamiliar face identity recognition; her navigational skills were also markedly impaired after she developed COVID-19. They reported that she performed poorly on all 4 tests. However, she performed normally on tests of face detection, face identity perception, object recognition, scene recognition, and non-visual memory.

Survey data that was self-reported by 54 individuals who responded to the survey “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported.

In Annie’s case, she resumed working from home in April 2020. However, she could not recognize her father when she saw him again after she recovered from her illness and she could not differentiate him from her uncle.

“My dad’s voice came out of a stranger’s face,” she said.

She also reported that she experienced problems getting around a grocery store and identifying her car in the lot.

The researchers summarized, “Annie's results indicate that COVID-19 can produce severe and selective neuropsychological impairment similar to deficits seen following brain damage, and it appears that high-level visual impairments are not uncommon in people with long COVID."

Reference
1. Kieseler M-L, Duchaine B. Persistent prosopagnosia following COVID-19. Cortex. 2023; Published online March 9, 2023; https://doi.org/10.1016/j.cortex.2023.01.012Get rights and content
Related Videos
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
© 2024 MJH Life Sciences

All rights reserved.